Navigation Links
QRxPharma Successfully Completes Phase 1 Studies for MoxDuo® CR
Date:4/10/2012

BEDMINSTER, N.J. and SYDNEY, April 10, 2012 /PRNewswire/ -- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today successful completion of two Phase 1 studies in healthy volunteers for MoxDuo® CR, a controlled-release Dual-Opioid® utilising a 3:2 ratio of morphine and oxycodone. The proprietary MoxDuo CR formulation, encompassing both sustained delivery technology as well as abuse deterrent and tamper resistant features, is designed to provide at least 12 hours of analgesia in patients suffering from moderate to severe chronic pain including cancer, lower back, osteoarthritis and neuropathic pain. The clinical trials compared blood levels of MoxDuo CR's components to OxyContin® and MS Contin® and demonstrated MoxDuo CR's superior results, with sustained blood levels for up to 24 hours. Further studies indicated MoxDuo CR's increased resistance to tampering.

"The successful completion of these trials confirms the advantages of this formulation and enables QRxPharma to initiate Phase 2 Proof-of-Concept clinical studies mid-year 2012," said Dr. John Holaday, Managing Director and Chief Executive Officer of QRxPharma. "These data suggest MoxDuo CR may be positioned as a once or twice per day formulation for treating chronic pain, with the potential advantage of significantly reduced side effects as witnessed with immediate release MoxDuo. In the US alone, the chronic opioid pain market is a $6 billion a year opportunity."

Two Phase 1 trials were conducted in healthy volunteers to evaluate the rate at which key components of the MoxDuo controlled-release (CR) formulation were absorbed, distributed, metabolised and eliminated by the body. The first study compared MoxDuo CR (30mg morphine SO4/20mg oxycodone HCl) to the pharmacokinetic profiles of the same doses of MS Contin (30mg morphine SO4) and OxyContin (20 mg oxycodone HCl) in 10 healthy adult human subjects using a three-way crossover design. Pharmacokinetic results from the measu
'/>"/>

SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 Bronstein, Gewirtz & ... purchasers of the securities of PDL BioPharma, Inc. ("PDL ... -News).  Such investors are advised to contact Peretz ... Kimelman at info@bgandg.com or 212-697-6484. ... certain of its executives violated federal securities laws. ...
(Date:9/17/2014)... 2014 , Glenmark,s ... positive data in a Phase 2a proof of concept ... Glenmark Pharmaceuticals today announced that its ... antagonist, GRC 17536 has shown positive data in a ... concept study conducted on 138 patients in ...
(Date:9/17/2014)... 17, 2014   MedeAnalytics today unveils ... brings complete visibility to a provider,s "mid-cycle" to ... reimbursement landscape. Powered by the industry,s leading big ... critical point between patient access and the business ... will improve revenue capture, minimize audit risk and ...
Breaking Medicine Technology:Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
... Oct. 31, 2011 Covance Inc. (NYSE: ... ranked first, by a wide margin, in an independent ... trials. The majority (54 percent) of the study participants ... central laboratory, with investigators citing Covance three times more ...
... InterMune, Inc. (NASDAQ: ITMN ) today ... Shire plc, has been appointed to InterMune,s Board of ... on meeting the needs of the specialist physician. ... a leading global biopharmaceutical company with expertise in the ...
Cached Medicine Technology:Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey 2Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey 3InterMune Appoints Angus C. Russell to Board of Directors 2InterMune Appoints Angus C. Russell to Board of Directors 3
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... The Food and Drug Administration (FDA) has ... consider: , 1. The appropriate indicated ... 2. The potential for adverse cardiovascular outcomes associated ... ongoing, an informally-organized litigation group subcommittee prepared a presentation ... therapy. Among others, ZKB attorney Michelle L. Kranz and ...
(Date:9/17/2014)... CA (PRWEB) September 17, 2014 ... University, revealed 12 companies raising rounds of funding at ... a few hundred investors and media, was the first ... headquarters located next to the university. The presentations were ... volunteers, adjacent to StartX-QB3 Labs, a 2,000 square foot ...
(Date:9/17/2014)... Cadiz Laser Spa offers the latest, most ... throughout Central Texas. The newest addition to their ... Using the revolutionary Rejuvapen micro-needling device Cadiz Laser ... a wide variety of skin issues. , The ... Spa is currently offering a special package through ...
(Date:9/17/2014)... News) -- Present-day Europeans are the descendants of ... to a new study. Previous research ... early European farmers. But, a new genetic analysis ... the descendants of Ancient North Eurasians. Nearly all ... ancestral group, researchers from Harvard Medical School said. ...
Breaking Medicine News(10 mins):Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:FDA Advisory Committee Holds Hearing on Testosterone Safety 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:Revolutionary Collagen Induction Therapy is Now Available at Cadiz Laser Spa 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3
... in 2007, Blue Cross Blue Shield of Georgia (BCBSGa) announced ... clinical psychologists by approximately 19%. This new rate is ... home handyman per hour. However, unlike your mechanic, BCBSGa ... were paid 10 years ago by BCBSGa. In 1998 ...
... Care innovations and opportunities attract attendees from more than ... 6th Annual World Health Care Congress April 14-16, 2009, ... Muhammad Yunus of the Grameen Bank and a delegation ... from more than a dozen other countries at the ...
... Improve Community SafetyJEFFERSON CITY, Mo. , April 7 ... and Parole has launched a new alcohol monitoring Pilot ... alcohol monitoring on the management of the state,s alcohol-fueled ... offenders with a documented history of alcohol abuse and ...
... WASHINGTON, April 7 Dr. Michael J. Kussman, the Under ... today announced his intention to retire from federal service by ... who attained the rank of brigadier general while in the ... for Health since 2007, Dr. Kussman has directed a health ...
... connection between out-of-pocket expenses for people contending with ... antidepressant treatment. , Dr. Carolyn Dewa, head of ... at the Centre of Addiction and Mental Health ... of money spent on medication before a disability ...
... provider of Microsoft Dynamics CRM ... live, Resurrection Health Care experienced a 50% increase in ... health care provider, is a family of health care ... services, behavioral health services and numerous outpatient centers. , ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Georgia Is Skimping on Mental Health Care, Says Georgia Psychological Association 2Health News:Blue Cross Blue Shield of Georgia Is Skimping on Mental Health Care, Says Georgia Psychological Association 3Health News:Nobel Prize Winner Professor Muhammad Yunus Leading Delegation From Bangladesh to World Health Care Congress to Advance Affordable Health Care Innovations 2Health News:Nobel Prize Winner Professor Muhammad Yunus Leading Delegation From Bangladesh to World Health Care Congress to Advance Affordable Health Care Innovations 3Health News:Nobel Prize Winner Professor Muhammad Yunus Leading Delegation From Bangladesh to World Health Care Congress to Advance Affordable Health Care Innovations 4Health News:Missouri DOC Conducting Pilot of 24/7 Alcohol Anklets 2Health News:Missouri DOC Conducting Pilot of 24/7 Alcohol Anklets 3Health News:Michael J. Kussman, VA Under Secretary for Health, to Retire 2Health News:When physical and mental health problems co-occur and money gets tight, which prescriptions go unfilled? 2Health News:Resurrection Health Care Increases Sales Productivity by 50% Since Implementing Microsoft Dynamics CRM 2Health News:Resurrection Health Care Increases Sales Productivity by 50% Since Implementing Microsoft Dynamics CRM 3
This 100 µL is the equivalent to the "Universal Blue" tips and fits virtually every manufacturer's 1000 µL Pipettor....
Conducting disposable tips provide cross-contaminationfree pipetting for sensitive applications such as PCR setup....
Volume range 0.2-10 l. Designed for pipetting micro-sized drops. Ideal for use with micro volume Finnpipettes....
Conducting disposable tips....
Medicine Products: